Biotech Values

[DewDiligence]

PFE’s maternal RSV vaccine meets one of two primary endpoints, which PFE says is sufficient for FDA approval:

https://finance.yahoo.com/news/pfizer-announces-positive-top-line-103000293.html

The pre-planned, interim efficacy analysis conducted by an external and independent Data Monitoring Committee (DMC) met the success criterion for one of two primary endpoints. The observed efficacy for severe medically attended lower respiratory tract illness (severe MA-LRTI) was 81.8% (CI: 40.6%, 96.3%) through the first 90 days of life.

… Although the statistical success criterion was not met for the second primary endpoint [prevention of hospitalization] clinically meaningful efficacy was observed for MA-LRTI of 57.1% (CI: 14.7%, 79.8%) in infants from birth through the first 90 days of life.